The Case of the Immunotherapy Inquiry
Jay is a 62-year-old man with newly diagnosed, stage IIIA (T3, N1), unresectable, non-small cell lung cancer (NSCLC) that tested negative for ALK, EGFR, and KRAS mutations. Additionally, PD-L1 (programed death receptor ligand) expression was less than 30%. Jay is symptomatic with a persistent cough, unintentional weight loss, and fatigue.
FDA Approves Marketing of First Digital Pathology Whole Slide Imaging System
The U.S. Food and Drug Administration (FDA) has permitted marketing of the Philips IntelliSite Pathology Solution (PIPS, Philips Medical Systems Nederland B.V.), as an aid to the pathologist to review and interpret digital images of surgical pathology slides prepared from formalin-fixed paraffin embedded (FFPE) tissue.
FDA Removes Risk Evaluation Management Strategies (REMS) for ESAs
On April 13, 2017, the U.S. Food and Drug Administration (FDA) removed the Risk Evaluation and Mitigation Strategy (REMS) requirements for the use of Epogen/Procrit and Aranesp to treat patients with anemia due to associated myelosuppressive chemotherapy.
HPV Vaccines Fight Against Oral Cancers and More
Because April is Oral Cancer Awareness Month, it’s important to understand the link between human papillomavirus (HPV) and oropharyngeal cancers. This form of oral cancer occurs in the middle part of the throat, soft palate, base of the tongue, and tonsils. HPV contributes to more than 70% of all oropharyngeal cancers, with more than half of these being related to HPV type 16. The Centers for Disease Control and Prevention (CDC) noted that approximately 9,000 new cases of oropharyngeal cancers are diagnosed annually and are typically four times more common in men than women.
FDA Approves Ribociclib for Breast Cancer Treatment
On March 13, 2017, the U.S. Food and Drug Administration (FDA) approved ribociclib (KISQALI®, Novartis Pharmaceuticals Corp.), a cyclin-dependent kinase 4/6 inhibitor, in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
ONS and ASCO CancerLinQ Partnership Will Help Institutions Use Practice Data to Drive Greater Cancer Care
Offering personalized treatment plans to patients with cancer is one of the biggest goals for any oncology institution—big or small. ONS leaders and members have united their personal and organizational efforts to move cancer care toward personalization while still aligning the needs of patients with nationally recognized clinical guidelines. Oncology nurses consistently strive to deliver quality cancer care to their patients.
Sepsis Identification and Early Goal-Directed Therapy
Infection represents a leading cause of death and treatment-related toxicities among patients with cancer in the United States. It stands to interfere with antineoplastic treatment plans by forcing dose modifications, delays, or discontinuation and instead turning to a less aggressive treatment plan.
Nurses Lend Voice to End-of-Life Decisions
Patients rely on oncology nurses to translate the world of health care. They lean heavily on our expert knowledge when undergoing treatments for cancer. It’s not simply the facts we provide—like the pros and cons of a certain treatment—it’s helping patients understand how these facts impact their lives. This knowledge allows patients nearing the end of life to make informed decisions about whether they should continue treatment or seek referral to hospice care.
The Case of the Breast Cancer Biology
Molly is a 48-year-old biology professor at a prestigious university. She was recently diagnosed with stage II invasive ductal carcinoma. She is referred to Anna, the breast nurse navigator, for breast cancer education and coordination of care.
The Case of the Dietary Dilemma
Cicely, who is being treated for stage III colon cancer, has lost seven pounds between her first and second cycles of chemotherapy. She admits to Julie, an outpatient oncology nurse, that her nausea is well controlled but she just doesn’t feel like cooking meals anymore. What Would you do?
What Is ONS’s Stance on Handling Chemotherapy While Pregnant, Breastfeeding, or Trying to Conceive?
One of the questions that ONS commonly receives in the clinical inbox is whether nurses who are pregnant, breastfeeding, or trying to conceive can safely administer or handle chemotherapy and other hazardous drugs.
The Case of the Caregiver With Cancer
APRNs Now Have Full Medical Authority in Practice at VA Hospitals
What Oncology Nurses Need to Know About Biosimilar Drugs
Generic, bioidentical, and biosimilar are terms used to identify a drug that has a comparable chemical structure and intended effect as the original patented drug. However, the terms are not necessarily interchangeable. The differences between these can impact the way you practice.
Identifying Medication Errors in Hospice Care
Nurses Dispel Myths, Offer Valuable Education About Palliative Care
The Case of the Facebook Friend Request
Embracing Quality Manager Roles
The Case of the Targeted Therapy Misperception
Addressing the Challenge of CLABSI Prevention
How Do You Bridge the Gap Between Ethical Dilemmas and Spirituality?
Learning More About Point-of-Care Practices for Neutropenia
Addressing the Challenge of CLABSI Prevention
The Case of the Decision-Making Dilemma
How Do I Become an Oncology Nurse?
What Oncology Nurses Should Know About the Zika Virus
Elevate Your Practice Through Continuing Nursing Education
Four Ways to Help Patients With Cancer Overcome Fatigue
Manage Common Ocular Toxicities From Tyrosine Kinase Inhibitors
Genetic Testing Is Important for Survivorship
Cancer survivorship is filled with many challenges, hopes, and expectations. June 5 marks National Survivorship Day, and survivorship is being celebrated throughout the month. Survivors are often not sure where they're going once their cancer journey commences. In my practice, I care for people with a genetic risk for cancer, and I work with survivors on a regular basis.
The Psychological Benefits of Cancer Prehabilitation
Cancer prehabilitation is a whole-person approach to quality cancer care. Along with potential physical gains, patients who participate in cancer prehabilitation (interventions started prior to cancer therapies) may also benefit emotionally and socially. The Case of the Deconditioned Patient focused on the physical benefits Frank experienced as a result of attending prehabilitation before he had surgery for lung cancer. Frank’s psychological gains were no less impressive.
The Case of the Deconditioned Patient
Seven Simple Strategies Addressing Health Literacy
I was more than a bit nervous to make the call. After all, she was a biology professor and knew more about life on a cellular level than I could possibly fathom. She had just been diagnosed with breast cancer. And I was calling to educate her?
Navigating Moral Distress in the Face of Ethical Dilemmas
Outpatient Staffing Model Improves RN Roles and Functionalities
The Case of the Clinical Trial Candidate
The Impact of Complex Care Needs on Nursing Education
What Oncology Nurses Need to Know About Supporting AYAs With Cancer
The Amazing Power Of A Smile
Palliative Care Initiated in the Emergency Department Improves Patients’ Quality of Life
Addressing Myths About Family History and Cancer Risk
Urban legends. Myths. Sometimes you should not believe everything you hear or read. The more emotionally charged the issue, often the bigger the myth. In my practice of providing cancer risk assessment and genetics education and counseling, patients often thank me at the end of the session and tell me they are going to explore the information more extensively at home on the internet.